Market Overview

UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Celgene Corporation

Related CELG
Biotech Stock Roundup: MannKind PDUFA Date Pushed Out, Alkermes Impresses with Data - Analyst Blog
Stock Market News for April 14, 2014 - Market News

In a report published Friday, Jefferies reiterated its Buy rating on Celgene Corporation (NASDAQ: CELG), and raised its price target from $104.00 to $114.00.

Jefferies noted, “On its 4Q earnings call, CELG focused details around achieving the 2017 guidance laid out earlier this month. We are raising our price target from $104 to $114 as we are adding modest apremilast to our valuation and raising our expectations for Abraxane penetration in pancreatic cancer following positive Phase 3 data released yesterday.”

Celgene Corporation closed on Thursday at $97.49.

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (CELG)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free